Sanofi SA (SNY)
48.28
+0.30
(+0.63%)
USD |
NASDAQ |
Nov 22, 16:00
48.35
+0.07
(+0.14%)
Pre-Market: 20:00
Sanofi Revenue (Annual): 50.28B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 50.28B |
| December 31, 2022 | 47.87B |
| December 31, 2021 | 46.35B |
| December 31, 2020 | 42.68B |
| December 31, 2019 | 42.13B |
| December 31, 2018 | 42.13B |
| December 31, 2017 | 41.02B |
| December 31, 2016 | 38.40B |
| December 31, 2015 | 38.69B |
| December 31, 2014 | 42.55B |
| December 31, 2013 | 41.56B |
| December 31, 2012 | 46.23B |
| December 31, 2011 | 48.88B |
| Date | Value |
|---|---|
| December 31, 2010 | 45.11B |
| December 31, 2009 | 42.88B |
| December 31, 2008 | 42.30B |
| December 31, 2007 | 40.04B |
| December 31, 2006 | 37.06B |
| December 31, 2005 | 35.46B |
| December 31, 2004 | 19.55B |
| December 31, 2003 | 9.096B |
| December 31, 2002 | 7.051B |
| December 31, 2001 | 5.812B |
| December 31, 2000 | 5.509B |
| December 31, 1999 | 5.697B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
42.13B
Minimum
2019
50.28B
Maximum
2023
45.86B
Average
46.35B
Median
2021
Revenue (Annual) Benchmarks
| AstraZeneca PLC | 45.81B |
| GSK PLC | 37.74B |
| Eli Lilly and Co | 34.12B |
| Novavax Inc | 556.38M |
| Regeneron Pharmaceuticals Inc | 13.12B |